Potential risk analysis of valganciclovir/vansevir

As a prescription antiviral drug, Valganciclovir has definite efficacy in preventing and treating cytomegalovirus (CMV) infection, but there are also potential risks during its use, which need to be fully weighed between patients and doctors. The drug will be metabolized into a more active form in the body - Ganciclovir. Although this active metabolite can effectively inhibit viral replication, it may also affect the DNA synthesis of normal cells in the human body, thus causing a series of adverse reactions.

First, myelosuppression is the most common adverse reaction of valganciclovir and the highest clinical concern. After long-term use, patients may experience leukopenia, platelet decline, anemia and other problems, which are particularly significant in people with low immune function. Since drugs are closely related to the immune system, blood levels need to be monitored regularly during medication to avoid the risk of serious infection or bleeding.

Secondly, kidney function impairment is also a potential risk that needs attention. Valganciclovir is mainly metabolized and excreted by the kidneys. If the patient has renal insufficiency, the drug may accumulate in the body and increase toxic reactions. Therefore, in clinical practice, doctors will adjust the dose according to the patient's renal function to reduce the risk. At the same time, patients also need to avoid concurrent use of other drugs that may increase the burden on the kidneys.

In addition, long-term use of valganciclovir may also have effects on the nervous system and gastrointestinal tract, such as headache, fatigue, nausea, diarrhea, etc. Although most of these symptoms are mild to moderate, if not taken seriously, they may affect patient compliance and treatment continuity. More importantly, some experimental and clinical data suggest that the drug may have potential effects on the reproductive system, so people of childbearing age should be particularly cautious during use.

Reference materials:https://go.drugbank.com/drugs/DB01610